AusBiotech has welcomed the appointment of its former CEO, Dr Anna Lavelle, as the new chair of Medicines Australia.
Medicines Australia is the representative body of the Australian research-based pharmaceutical industry.
Dr Lavelle joined the association's Board in early 2017 following her retirement from AusBiotech after 11 years as its CEO.
She succeeds outgoing chair, Wes Cook, the managing director of Boehringer Ingelheim, who spent three years in the role and played the leading role in the negotiation of the association's 2017 strategic agreement with the federal government.
Medicines Australia now joins AusBiotech in having an all-female leadership team. Dr Lavelle's appointment as its first female chair follows Liz de Somer's recent appointment as the association's first female CEO.
"I am thrilled to have the opportunity to work alongside Dr Lavelle and to represent the first female leadership team for Medicines Australia," said Ms de Somer.
"I am delighted to acknowledge and welcome Dr Lavelle's appointment as Chair of Medicines Australia, as an important choice that will see her immense talent, network, expertise and experience in leading the industry," said AusBiotech CEO Lorraine Chiroiu.
"Having been privileged to have worked closely with Dr Lavelle over many years, this appointment gives me great confidence that Australia's Industry will continue to develop on its trajectory from strength to strength."